Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Describes the Forma-Celgene 'expansive alliance' in protein homeostasis, presenting the multi-year, milestone-rich partnership as a significant strategic…
FierceBiotech framed the 2013 deal as Celgene tapping Forma in 'the hot field of protein homeostasis,' situating it alongside validated proteasome (Velcade,…
BioPharma Dive reported Celgene paying $195M to extend the Forma alliance through 2019, with continued option to acquire Forma — characterizing the high…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Celgene-Forma initial collaboration to discover/develop small molecules targeting protein homeostasis; up to $200M in research and early development funding; Forma led through Phase 1, Celgene took over post.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Forma Therapeutics Holdings Inc. (this deal) | 2013 | $200M | — |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Receptos Inc. | 2015 | $7.2B | 63 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
← Browse all deals · How we score deals
More: 2013 deals · Celgene Corporation deals · Oncology deals